Pharma Industry News

NICE rejects Janssen’s Stelara on cost efficiency grounds

The annual treatment costs are £14,482 in the induction year, and £9,304 per year for maintenance treatment.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]